Heart Function in People With Leg Artery Disease
Studies heart pumping changes in adults with narrowed leg arteries using strain imaging.
Plain-language title generated from the registry record
Registry title: Myocardial Dysfunction Evaluation in Lower Extremity Arterial Disease Patients With Deformation Analysis
Key facts
- Where
- Tartu, EstoniaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 35-85 with lower extremity arterial disease (LEAD), plus a control group with heart-risk factors such as high blood pressure, diabetes, coronary artery disease or smoking.
- Age
- 35 to 85 years
- Sex
- All sexes
- Disease stage
- LEAD group: confirmed lower extremity arterial disease with Fontaine I-IV class symptoms. Control group: at least one of hypertension, diabetes, coronary artery disease or smoking.
- Earlier treatment
- People cannot join if they had treatment for heart valve disease, chest radiation for a tumor, or cancer drug or biologic treatment.
Main reasons for not taking part
- Known heart failure
- Heart muscle or structural heart disease, or moderate to severe heart valve disease
- Acute coronary syndrome, transient ischemic attack or stroke in the last 3 months
- Severe kidney or liver dysfunction
- Cancer with less than 5 years of remission
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 85 years old?
Source: NCT06215248, who can take part
Where in Estonia
- Tartu University HospitalTartu, EstoniaContact: Liis Roine, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tartu University Hospital
- Trial code
- NCT06215248
- Record updated
- 16 December 2025
- Original description
Single centre observational study to assess lower extremity arterial disease (LEAD) patients' cardiac dysfunction with strain analyses and to assess connections between cardiac dysfunction, metabolomic changes and target organ damage in LEAD.Read full original descriptionShow less
Assessment of Dysfunction in Left Cardiac Chambers With Strain-analyses in Patients With Lower Extremity Arterial Disease
Single centre observational study to assess lower extremity arterial disease (LEAD) patients' cardiac dysfunction with strain analyses and to assess connections between cardiac dysfunction, metabolomic changes and target organ damage in LEAD.
Inclusion: Fontaine I-IV class symptoms; Confirmed diagnosis of LEAD; Age 35-85; Has to have at least of the following: hypertension, diabetes, coronary artery disease or the patient smokes.
Exclusion: Known heart failure in history; Any acute or chronic autoimmune or rheumatic disease; Cardiac structural disease in history: inflammatory, infiltrative diseases, nonischemic cardiomyopathies; Acute coronary syndrome in last 3 months; Moderate to severe cardiac valvular disease; Cardiac valvular disease operative/invasive treatment in history; Cardiac implantable electronic device (CIED); Transitory ischemic attack or stroke in last 3 months; Untreated hypertension (noninvasive blood pressure measurement ≥180/110 mmHg during recruitment); Malignant tumor with radiation treatment to thorax, oncologic or biologic treatment in history; Chronic hematologic disease (except for anemia); Acute or chronic infectious disease; Chronic severe kidney dysfunction (eGFR <30 ml/min/1,73 m²); Anemia with hemoglobin <80 g/L; Age <35 or >85 years; Malignant tumor with <5 years of remission; BMI ≥40 kg/m²; Severe COPD (GOLD C or D); Moderate to severe asthma (according to GINA 2022 criteria); Severe liver dysfunction.